DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20205532

Vitamin D3 augments the antidepressant effect of agomelatine against repeated corticosterone-induced depressive-like behavior in rats

Hanan Tawfeek Emam, Nashwa Hassan Abu-Raia

Abstract


Background: Depression is a highly complex psychiatric disorder that remains a major burden on society. The present study was aimed to detect the neuroprotective effect of agomelatine or/and vitamin D3 on the progression of depression induced by chronic administration of corticosterone.

Methods: Rats were classified into 4 equal groups; corticosterone-untreated group, agomelatine-treated group, vitamin D3-treated group, and (agomelatine and vitamin D3)-treated group.

Results: Agomelatine or/and vitamin D3 caused significant improvement of behavioral parameters of depression, increase in serotonin, dopamine, and brain-derived neurotrophic factor (BDNF) with a significant decrease in tumor necrosis factor (TNF)-alpha and caspase-3 levels of brain tissue with a more significant effect of combination therapy over the effect of each drug alone.

Conclusions: Vitamin D3 augments the antidepressant effect of agomelatine against depressive-like behavior in rats.


Keywords


Depression, Agomelatine, Vitamin D3, Apoptosis, BDNF

Full Text:

PDF

References


Aminpoor H, Afshinfar J, Mostafaei A, Ostovar S. Validation of Goldberg's Depression Scale in academic and non-academic peoples. Ann Biological Res. 2012;3(9):4564-73.

Aan Het RM, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ. 2009;180:305-13.

Anacker C, Patricia A, Zunszain LAC, Carmine MP. The glucocorticoid receptor: Pivot of depression and of antidepressant treatment? Psycho-neuro-endocrinol. 2011;36(3):415-25.

Jesulola E, Micalos P, Baguley IJ. Understanding the pathophysiology of depression: From monaamines to the neurogenesis hypothesis model-are we there yet? Behavioural brain res. 2018;341:79-90.

Boas GRV, De Lacerda RB, Paes MM, Gubert P, Da Cruz Almeida WL, Rescia VC, et al. Molecular Aspects of Depression: A Review from neurobiology to treatment. Eur J pharmacol. 2019;851:99-121.

Goodwin GM, Emsley R, Rembry S. Agomelatine Study Group: Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:1128-37.

Fernandes DA, Eyles D, Féron F. Vitamin D, a neuro-immunomodulator: Implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinol. 2009;34:S265-77.

Eyles, D.W.; Burne, T.H. and McGrath, J.J. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol. 2013 Jan; 34(1):47-64.

Wang JY, Wu JN, Cherng TL, Hoffer BJ, Chen HH, Borlongan CV et al. Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res. 2001;904:67-75.

Stio M, Treves C, Martinesi M, Bonanomi AG. Biochemical effects of KH 1060 and anti-TNF monoclonal antibody on human peripheral blood mononuclear cells. Int Immunopharmacol, 2005;5:649-59.

Handel AE, Giovannoni G, Ebers GC. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol. 2010;6:156-66.

Xie X, Shen Q, Ma L, Chen Y, Zhao B, Fu Z. Chronic corticosterone-induced depression mediates premature aging in rats. J Affect Disord. 2018;229:254-61.

Ali AA, Rahman Z, Alwakeel AI, Masoud MA, Elansary AK. Comparative Study on the Activity of Agomelatine and/or Curcumin against Development of Depression in Rats. iMedPub j. 2016;2(4):33.

Hanaa HA, Samiha MA, Fatma MA, Heba AM. Significance of vitamin D in combination with calcium in modulation of depression in the experimental model. Der Pharma Chemica, 2015;7(1):128-47.

Carrey N, McFadyen MP, Brown RE. Effects of chronic methylphenidate administration on the locomotor and exploratory behavior of prepubertal mice. J Child Adolescent Psychopharmacol. 2000:10:277-86.

Brown RE, Corey SC, Moore AK. Differences in measures of exploration and fear in MHC-congenic C57BL/6J and B6-H-2K mice. Behavior Genetics. 1999;26:263-71.

Venkatramaniah C, Praba MA, Ganesh K. Protective Role of Acorus Calamus and Beta Asarone In Exploration and Anxiety Levels on Experimental Epileptic Rat Model. Int J Anat Res. 2017;5(3.1):4067-72.

Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD. The Tail Suspension Test. J Vis Exp. 2012;59:e3769.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265-75.

Ciarlone EA. Determination of catecholamines spectrophoto-flurometrically. Am J Physiol. 1978;125:731-7.

Taylor PC. Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases. Mol Biotechnol. 2001;19(2):153-68.

Dekel T, Assaf L, Roman G, Sharon H, Alon C. Resilience to chronic stress is mediated by hippocampal brain-derived neurotrophic factor. J Neurosci. 2011;31(12):4475-83.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-CT method. Methods. 2001;25(4):402-8.

Yohn CN, Gergues MM, Samuels BA. The role of 5-HT receptors in depression. Molecular Brain. 2017;10:28.

Schmidt MV, Sterlemann V, Wagner K, Niederleitner B, Ganea K, Liebl C et al. Postnatal glucocorticoid excess due to pituitary glucocorticoid receptor deficiency: differential short- and long-term consequences. Endocrinol. 2009;150(6):2709-16.

Liu H, Kaur J, Dashtipour K, Kinyamu R, Ribak CE, Friedman LK. Suppression of hippocampal neurogenesis is associated with developmental stage, number of perinatal seizure episodes, and glucocorticosteroid level. Exp Neurol. 2003;184(1):196-213.

Dean J, Keshavan M. The neurobiology of depression: an integrated view. Asian J Psychiatr. 2017;27:101-11.

Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am. 2014;37:375-91.

Rainer Q, Xia L, Guilloux JP, Gabriel C, Mocaë RE, David DJ. Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. Int j neuropsychopharmacol. 2012;321(3):15-35.

Srinivasan V, Zakaria R, Othman Z, Lauterbach EC, Acuna-Castroviejo D, AgoSomwaru LL. The natural history of subclinical hypothyroidism in the elderly: the cardiovascular health study. J Clin Endocrinol Metabol. 2012;97:1962-9.

Treadway MT. The Neurobiology of Motivational Deficits in Depression‐‐An Update on Candidate Pathomechanisms. Curr Top Behav Neurosci. 2016;27:337‐55.

De Berardis D, Conti C, Marini S, Ferri F, Iasevoli F, Valchera A, et al. IS there a role for agomelatine in the treatment of anxiety disorders? A review of published data. Int J Immunopathol-Pharmacol. 2013;26(2):299-304.

Gumuslu E, Mutlu O, Sunnetci D, Ulak G, Celikyurt IK, Cine N, et al. The Antidepressant Agomelatine Improves Memory Deterioration and Upregulates CREB and BDNF Gene Expression Levels in Unpredictable Chronic Mild Stress (UCMS)-Exposed Mice. Drug Target Insights. 2014;8:11-21.

Patrick RP, Ames BN. Vitamin D hormone regulates serotonin synthesis. Part 1: Relevance for autism. FASEB J. 2014;28:2398-413.

Cui C, Song S, Cui J, Feng Y, Gao J, Jiang P. Vitamin D Receptor Activation Influences NADPH Oxidase (NOX2) Activity and Protects against Neurological Deficits and Apoptosis in a Rat Model of Traumatic Brain Injury. Oxidative Med Cell Longevity. 2017;2017:13.

Cohen-Lahav M, Shany S, Tobvin D, Chaimovitz C, Douvdevani A. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol Dial Transplant. 2006;21(4):889-97.